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Abstract
Background: Chemokines are a subset of cytokines responsible for controlling the cellular migration of inflammatory cells
through interaction with seven transmembrane G protein-coupled receptors. The blocking of a chemokine-receptor
interaction results in a reduced inflammatory response, and represents a possible anti-inflammatory strategy, a strategy that
is already employed by some virus and parasites. Anti-chemokine activity has been described in the extracts of tick salivary
glands, and we have recently described the cloning and characterization of such chemokine binding proteins from the
salivary glands, which we have named Evasins.
Methodology/Principal Findings: We have solved the structure of Evasin-1, a very small and highly selective chemokine-
binding protein, by x-ray crystallography and report that the structure is novel, with no obvious similarity to the previously
described structures of viral chemokine binding proteins. Moreover it does not possess a known fold. We have also solved
the structure of the complex of Evasin-1 and its high affinity ligand, CCL3. The complex is a 1:1 heterodimer in which the N-
terminal region of CCL3 forms numerous contacts with Evasin-1, including prominent p-p interactions between residues
Trp89 and Phe14 of the binding protein and Phe29 and Phe13 of the chemokine.
Conclusions/Significance: However, these interactions do not appear to be crucial for the selectivity of the binding protein,
since these residues are found in CCL5, which is not a ligand for Evasin-1. The selectivity of the interaction would appear to
lie in the N-terminal residues of the chemokine, which form the ‘‘address’’ whereas the hydrophobic interactions in the rest
of the complex would serve primarily to stabilize the complex. A thorough understanding of the binding mode of this small
protein, and its other family members, could be very informative in the design of potent neutralizing molecules of pro-
inflammatory mediators of the immune system, such as chemokines.
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Introduction
Chemokines (chemotactic cytokines) are a subset of cytokines
primarily responsible for controlling the cellular migration of
various inflammatory cells. They compose a large family
(approximately 40 known members in the human system)[1] of
small proteins which share a relatively low level of sequence
identity, but which display a remarkable structural homology,
since they all contain the same monomeric fold. Chemokines
control the migration of leukocytes through interaction with
members of the G protein-coupled receptor family which possess
seven transmembrane helices. The pairing of the chemokines to
their receptors has been carried out, mainly by receptor binding
assays, and has identified receptors that are specific (bind to a
single ligand) or shared (bind more than one ligand). The
association of certain receptors and ligands with disease has come
from many studies of their expression in biopsy samples and body
fluids, animal models and genetically engineered mice.
Dysregulation of the chemokine system can result in excessive
cellular recruitment, with dramatic implications in inflammatory
and autoimmune diseases[2]. Blocking the receptor-chemokine
interaction should have therapeutic value, since prevention of this
directional migration represents an effective anti-inflammatory
strategy. Numerous reports in animal models have provided
evidence to support this hypothesis using tools such as genetically
engineered mice, neutralizing antibodies, and receptor antago-
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nature - efficient strategies are employed by viruses and certain
parasites to elude their hosts’ immune system, and hence, an
inflammatory response[4–9]. The strategies employed by viruses
in the guise of cytokine and chemokine binding proteins, such as
those directed against IFNc, IL-18 and various chemokines have
been fairly well documented[10–18].
Blood sucking parasites such as ticks can feed from several hours
to several days, and thereby evade the host immune response.
Anti-chemokine activity has been described in the extracts of tick
salivary glands[5,19,20], and we have recently described the
cloning and characterization of such chemokine binding proteins
from a tick salivary gland cDNA library, which we have named
Evasins[21,22]. The first to be identified, Evasin-1, was shown to
bind to a subpopulation of the chemokine family, contrasting with
most of the known viral chemokine binding proteins which
demonstrate broad selectivity profiles. Evasin-1 is a small 94-
amino acid protein which binds CCL3/MIP-1a and CCL4/MIP-
1b with very high affinity (0.16 and 0.81 nM, respectively), and
also displays lower affinity binding (3.2 nM) to a closely related
member of the CC chemokine family, CCL18/ PARC. This
chemokine-binding protein does not share any relevant sequence
or structural homology to any other known proteins, notably the
viral chemokine-binding proteins, and moreover, is considerably
smaller, being only 10 kDa compared to the viral proteins which
range in size between 30–40 kDa.
Here we present the crystal structure of a complex between the
chemokine CCL3 and the small tick-derived chemokine binding
protein, Evasin-1. The interactions are totally different from those
described for the viral chemokine binding proteins, and may lead
to an understanding of an efficient way to selectively inhibit the
chemokine system. The structure of the complex provides the
structural framework for the exquisite selectivity demonstrated by
Evasin-1, which displays a particularly high affinity for CCL3, but
has only negligible affinity for the closely related chemokine
CCL5, which shares the same receptors as CCL3. The binding
activity of chimeric chemokine constructs, consisting of the amino
terminal region preceding the CC motif of one of these
chemokines, followed by the sequence of the other, suggest that
the binding modality may follow a two-step process, with the
amino terminus determining the selectivity.
Results
Architecture of Evasin-1
We have determined the crystal structure of both non-
glycosylated (accession code: 3 fpr) and glycosylated Evasin-1
(accession code: 3 fpt), to 1.7 A ˚ and 2.70 A ˚ respectively. The
structures are very similar, and the Ca can be superimposed with
an rmsd of 0.97 A ˚, considering 83 of the 100 amino acid residues
(segment aligned Asp8-Arg90). The structure of the non-
glycosylated form of Evasin-1, which was determined at higher
resolution, will be described below.
The crystal structure of the non-glycosylated Evasin-1 contains
two molecules per asymmetric unit, monomer A (Asp5-Asp91) and
monomer B (Gly10-Trp89). The terminal amino acid residues
Asp5 and Asp91 for monomer A, as well as Trp89 for monomer B
were modelled as alanines, as there is no unambiguous electron
density for their side-chains. In both monomers, the extreme N-
terminal and C-terminal regions, comprising the six-histidine tag,
are flexible and were not seen in the electron density maps.
The overall structure of the Evasin-1 molecule is boat shaped,
with approximate dimensions of 35 A ˚ 620 A ˚ 613 A ˚. The largest
dimension corresponds to the distance comprising the N-terminal
region, which is exposed to the solvent and is involved in the
chemokine binding, as shown later in the structure of the complex
with CCL3. A stereo view of the overall structure of the non-
glycosylated form of Evasin-1 is presented in Figure 1. This
tertiary structure of Evasin-1 represents a new fold of the a/b type.
A search against all the PDB structures deposited and currently
available in the PDB did not identify any related structure, as will
be discussed later in this paper.
The Evasin-1 secondary structure is composed of seven beta
strands forming three anti-parallel beta sheets, one short alpha
helix, and contains four disulfide bridges (Figure 2). The four
disulfide bridges consist of: Cys12-Cys33 connecting the N-
terminal region of strand b1with b3; Cys29-Cys70 connecting
the beginning of b3 with b6; Cys46-Cys75 connecting the strands
b5 with b7 in the beta sheet b5-b6-b7 and finally Cys65-Cys84
connecting the other two strands b6 with b7 in the same beta
sheet. The disulfide bridges are positioned along the interior of the
protein, forming a central core, and undoubtedly conferring
structural rigidity by stabilization of the protein core.
The overall architecture can be divided into two subdomains
(Figure 2). The first subdomain (the N-terminal subdomain) is
formed by two non-contiguous segments comprising the N-
terminal residues Asp5-Pro13, and the anti-parallel beta-pleated
sheet formed by b3 and b4 consisting on the segment from
residues Lys30-Thr39. The beta sheet formed by b3 and b4
contains a beta-hairpin of type I’. A hydrogen bond network
formed by Gln31-Glu38, Asp32-Gly35, Cys33-Gly35 and Cys33-
Thr36 holds this beta sheet together.
The N-terminal segment is extended through the surface of the
monomer and is covalently bound to the b3 strand via the disulfide
Figure 1. Overall structure of Evasin-1. A stereo view of the overall structure of the non-glycosylated form of Evasin-1 is presented.
doi:10.1371/journal.pone.0008514.g001
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terminal region is anchored not only by the disulfide bridge, but
also by an intricate hydrogen bond network that places the N-
terminal segment in an exposed and favourable position for
chemokine binding. This hydrogen bond network comprises the
N-terminal region interactions with b4 through Gly11-Glu38,
Cys12-Glu38, and with b3 through Pro13-Gln31. Residues Gln31
and Glu38 as well as Cys33, anchors the flexible N-terminal area.
The Gln31 side-chain interacts with the carbonyl atom of Pro13
and also establishes main-chain and side-chain hydrogen bonds
with Glu38, thereby stabilizing the beta sheet formed between b3
and b4.
The second, C-terminal, subdomain is also composed of two
non-contiguous segments comprising residues Phe14-Cys29 and
Ala40-Asp91. This subdomain is composed of five beta strands
(b1-b2-b5-b6-b7), and one alpha helix (a1). This subdomain
undoubtedly constitutes the central core of the protein, as
evidenced by the lower B-factors observed in this extended b-
sheet. The beta strands b1 and b2 form an anti-parallel beta sheet
containing a beta turn of type 1. The beta strands b5, b6 and b7
also form a twisted anti-parallel beta sheet. The two beta sheets
formed by b1-b2 and b5-b6-b7 interact together to form the
twisted beta-barrel (b1-b2-b5-b6-b7-b1), which is pointing to the
alpha helix on the top. b1 and b2 are bridged through the main-
chain hydrogen bond interactions between Ala17 and Thr25.
Asn19 plays an important function by holding the beta turn of type
I, due to the six hydrogen bonds that it makes with neighbouring
residues Thr21, Gly22, Tyr23. Remarkably the ND2 atom is not
involved in these interactions, which is consistent with it being a
glycosylation site, an observation that is confirmed in the
glycosylated structure of Evasin-1, as described later.
The a1 helix is positioned opposite of the twisted beta barrel
vortex subdomain (as depicted in Figure 1). This helix is placed in
a solvent exposed area and is held to the vortex through three
hydrogen bonds, one between the start of the helix and the end of
b2 Gly50-Val27, one between the middle of the helix and the C-
terminal Arg55-Arg86, and one at the end of the helix and the C-
terminal Met58-Arg86. The C-terminal loop points to the solvent,
presenting the aromatic residue Trp89 totally exposed and located
in a flexible region with a Ca B-factor=50.0 A ˚ 2, much higher
than the average B-factor =34.8 A ˚ 2 for the whole protein chain of
monomer A (B-factor for the Ca of monomer A =32.8 A ˚ 2,
calculated with BAVERAGE from CCP4, 1994).
Glycosylated Form of Evasin-1
Three glycosylation sites were initially predicted by primary
sequence analysis through a PROSITE search used for pattern
identification (http://www.expasy.org/prosite)[23]. A typical N-
glycosylation consensus pattern Asn-Xxx-Thr[24] was found for
Asn19-Lys20-Thr21, Asn34-Gly35-Thr36 and Asn42-Gly43-
Figure 2. Secondary structure of Evasin-1. The secondary structure, disulfide bridges, and glycosylation sites of Evasin-1 are shown.
doi:10.1371/journal.pone.0008514.g002
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chemokine binding (see Figure 2).
Crystals of the glycosylated tick chemokine binding protein
produced in Sf9 insect cells using the baculovirus expression
system were obtained as described in the Methods section. The
structure was solved by molecular replacement using the
previously determined structure of the non-glycosylated form of
Evasin-1. The unit cell contains 3 molecules per asymmetric unit:
monomer A (Asp8-His95), monomer B (Gly11-Trp89) and
monomer C (Asp8-Trp89). The corresponding solvent content of
67%[25] and the glycosylation content may explain the 2.70 A ˚
diffraction limit of the crystals. The three crystallographic distinct
molecules are very similar with a rmsd for Ca atoms superposition
of 0.68 A ˚ for the superposition of monomers A and B, 0.77 A ˚ for
monomers B and C, and 0.95 A ˚ for monomers B and C, with the
greatest differences being observed for the residues at the termini.
Monomer A had the lowest overall B-factor (53.9A
3) compared to
the other two monomers, had the largest stretch of visible amino
acids (8 to 95), and will thus be used as the reference glycosylated
structure in the discussion below.
Residue Asn19 was the only one of the three predicted
glycosylation sites, which displayed clear electron density for a
sugar moiety. Only one saccharide unit, built as an N-acetyl D-
glucosamine, could be successfully modelled into all three
monomers of Evasin1-glycosylated on residue Asn19. There was
some unclear electron density visible for the next monosaccharide
in monomer A, and it was thus not modelled. Asn19 is at the C-
terminal end of the 1
st b-strand (b1) and is well exposed to solvent.
There is a clear hydrogen bond interaction between the acetamide
group of the glucosamine and the side chain of Thr22.
Architecture of the Complex between Evasin-1 and CCL3
In order to understand the structural basis of the chemokine
binding mechanism by Evasin-1, we have crystallized the complex
(accession code: 3 fpu) between Evasin-1 and a variant of the
human chemokine CCL3 (Figure 3). The crystal structure was
refined up to 1.9 A ˚ resolution, and it helps to clarify the structural
features of the binding mode of a new class of chemokine binding
proteins. One single complex of Evasin-1 and CCL3 crystallised in
the asymmetric unit.
One monomer of Evasin-1 binds one monomer of CCL3
displaying a 1:1 stoichiometry. Upon complex formation, the N-
terminal region of CCL3 interacts with both the N-terminal and
C-terminal regions of Evasin-1. These extremities, which are not
completely visible in the isolated crystal structures due to their
intrinsic disorder and flexibility, become more rigid due to a
network of interactions between the two proteins when the
complex is formed. As a consequence, some additional secondary
structure elements become visible. In the refined structure of the
complex, it is possible to identify the entire Evasin-1 molecule in
the electron density, as well as the CCL3 structure with the
exception of the last 2 residues of the C-terminus. The crystal
structure reveals the C-terminal polyhistidine tag, and includes
two metal ions, modelled as Ni
2+ atom (believed to be leached
from the IMAC resin during purification) and which play an
important role in establishing the crystal lattice.
The overall topologies of both Evasin-1 and CCL3 in the
complex are similar to the isolated crystallographic structures. The
Ca superposition of the isolated Evasin-1 (monomer A) with the
respective structure in the complex gives an overall rmsd of 1.0 A ˚.
The Ca superposition of the crystallographic structure of the
CCL3 (J. Dias, unpublished results) and the respective structure of
CCL3 in the complex also gives an overall rmsd of 1.0 A ˚,
considering only the C-terminal 50 amino acid residues.
The complex formation induces the stabilization of the entire N-
terminal and C-terminal areas of Evasin-1 and of the N-terminal
segment of CCL3, which becomes visible in the electron density
maps, showing the rearrangement of both N-terminal ends upon
binding. Due to interactions in the complex, the CCL3 N-terminal
region (residues Ser2-Thr10) moves by almost 90 degrees with
5AlaB moving circa 20 A ˚ (Figure 4). This difference in the
structure of the free and Evasin-1 bound structure is due essentially
to rotation around the Pro8-Thr9 and Thr9-Thr10 peptide bonds.
Three additional secondary structure elements are formed upon
binding: the a2 3-10 helix at the C-terminal of Evasin-1; and the
a0 3-10 helix and b0 strand at the N-terminal region of CCL3.
The additional CCL3 b0 strand interacts with the Evasin-1 b1
forming an antiparallel beta-sheet, which extends to Evasin-1 b2.
The newly formed CCL3a0 (Ala4A-Asp6A) interacts with the
newly formed Evasin-1 a2 3-10 suggesting that this stabilization
occurs in a cooperative manner.
Due to stabilization of the structures promoted by the
interaction within the complex, and due to the crystal packing,
the C-terminal of Evasin-1 becomes visible and the 3–10 helix
formed by Trp89A-Lys92A is revealed. The Trp89A is perfectly
visible (see Figure 5c) in the electron density map for the complex,
and the interacting residue Phe29B goes through a rotamer
change in order to accommodate this hydrophobic interaction.
Domain Interactions at the Interface of the Complex
The total buried surface area at the interface of the complex is
2650.58 A ˚ 2 as determined by CNX[26] or 2923.5 A ˚ 2 as
Figure 3. Stereo diagram of the complex between Evasin-1 and CCL3. The Evasin-1 is colored in cyan and CCL3 in green.
doi:10.1371/journal.pone.0008514.g003
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complementarity of the Evasin-1 /CCL3 interface was calculated
with SC from CCP4 to be Sc=0.76 using a 1.7 A ˚ probe sphere
radius[28].
The chemokine-binding region of Evasin-1 is an extended
region comprising both the N-terminal and C-terminal regions,
which embrace the chemokine. The interface of the complex was
calculated with CNX and LIGPLOT/HBPLUS and followed by
visual inspection and is summarized in Table S1). This interface
comprises 35 residues from the Evasin-1 and 27 residues of CCL3.
The hydrogen bond network at the interface of the complex is
composed of 25 hydrogen bonds, consisting in the interaction of
18 residues from the Evasin-1 and 12 residues of CCL3
(CONTACT from CCP4[29]).
Three specific residues of CCL3, Thr16B-Ser17B-Arg18B, are
targeted by the N-terminal region of Evasin-1, through 7 hydrogen
bonds (Figure 5a). The main-chain of the N-terminal residues
Asp3A-Leu9A of Evasin-1 interacts with the side-chain of this
unique segment of CCL3. This interaction is very specific since it
targets mainly the side-chains of this Thr16B-Ser17B-Arg18B
motif, which is unique to CCL3. A sequence alignment of
chemokines revealed a maximum of two identical residues, but
never the exact three-residue motif. The region of CCL3 may thus
be an important determinant of the unusual selectivity of Evasin-1.
The N-terminal b1 strand of Evasin-1 interacts with the Thr9B-
Cys11B N-terminal region of CCL3 through 3 hydrogen bonds,
inducing a short anti-parallel beta strand conformation upon
complex formation, assigned as strand b0 and formed by Thr10B-
Cys11B. The N-terminal contacts include several hydrophobic
interactions, one of which is an important edge-to-face p-p
interaction between Phe14A from Evasin-1 and Phe13B from
CCL3. This hydrophobic interaction is strengthened by a main-
chain hydrogen bond interaction between Evasin-1 Phe14A and
CCL3 Cys11B, connecting both N-terminal regions and holding
Phe14A in the appropriate environment (Figure 5b). Surrounding
the Phe14A-Phe13B interaction, there is a hydrophobic patch in
Evasin-1 formed by residues: Pro13A, Phe14A Tyr23A, Pro24A,
Ile26A, Ala40A, Pro41A, while the corresponding CCL3 adjacent
‘‘hydrophobic’’ region is formed by the disulfide bridges between
Cys11B-Cys35B and Cys12B-Cys51B, which lie in the vicinity (less
than 4 A ˚) of Pro24A and Pro13A, respectively.
The C-terminal of Evasin-1 embraces the N-terminal part of
CCL3 due to an important network of hydrogen bonds and
comprising a very important hydrophobic stacking interaction
between the Trp89A from Evasin-1 and Phe29B of CCL3 (see
Figure 5c). The aromatic side chains of Trp89A from Evasin-1,
and Phe29B CCL3 are arranged parallel but slightly off centre, as
observed in Figure 5c. Trp89A NE1 of Evasin-1 also interacts with
Gln49B OE1 from CCL3, which anchors the Trp89A in a
favourable position for the aromatic stacking with Phe29B from
CCL3. The N-terminal domain of CCL3 plays a major role in the
interaction with Evasin-1 by forming a lid to the pocket that
anchors Trp89A from Evasin-1. The segment after the N-terminal
helix of CCL3 composed by the residues: Ala5B-Asp6B-Thr7B-
Pro8B-Thr9B-Thr10B encloses the Trp89A (Evasin-1) – Phe29B
(CCL3) interaction. CCL3 Pro8B fits in the pocket of Evasin-1
defined by: strands b1 (Leu15A) and b7 (Arg86A, Asn88A,
Trp89A), with some side-chains from helix a1 (Leu54A, Arg55A),
interacting with Gln49B via a bridging water, contributing to the
positioning the hydrogen bond Gln49B OE1-NE1 Trp89A
Evasin-1.
Electrostatic Complementarity
The relatively small difference in the isoelectric points (pI) of
Evasin-1 (pI=6.0) and CCL3 (pI=4.9), compared to more basic
chemokines like RANTES (pI=9.3), may suggest that hydropho-
bic interactions are the main driving forces for the complex
formation between Evasin-1 and CCL3. Nevertheless, and despite
the relatively small difference in the overall protein charge, there is
a remarkable electrostatic surface complementarity at the contact
interface of the complex that enhances the complex interactions
(Figure 6). A remarkable feature at the interface of the complex is
the electrostatic complementarity observed surrounding the
aromatic stacking interaction between Trp89A-Phe29B, in which
the Phe29B belonging to CCL3 is buried in a negatively charged
pocket due to the presence of Glu30B and to the proximity of
Asp6B from CCL3 N-terminal region. On the other hand, the
Trp89A is enclosed in the positive C-terminal of Evasin-1. The
Trp89A-Phe29B interaction is surrounded by an electrostatic ring
that helps to orient both partner molecules, guiding the protein
docking through an electrostatic field.
Discussion
Novelty of the Evasin-1 Structure
Several aspects of the structure of the complex between Evasin-
1 and CCL3 are striking. A preliminary analysis of the amino acid
sequences of Evasin-1 by BLAST and PHI-BLAST had revealed
Figure 4. Stereo diagram of the comparison of unbound CCL3 with CCL3 bound to Evasin-1. The unbound form of CCL3 is shown in red,
the bound form displayed in green.
doi:10.1371/journal.pone.0008514.g004
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8514Figure 5. Close-up of the interactions between Evasin-1 and CCL3. The Evasin-1 is colored in cyan and CCL3 in green. (A) Interaction between
the Thr16-Ser17-Arg18 loop of CCL3 with Evasin-1 (B) Interaction between Phe13 of CCL3 and Phe14 of Evasin-1 (C) Interaction between Phe29 of CCL3
and Trp89 of Evasin-1 (D) 2Fo-fc electron density map, contoured at 1.5s of the interaction of the N-terminal region of CCL3 with Evasin-1.
doi:10.1371/journal.pone.0008514.g005
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have recently identified two other chemokine binding proteins
from tick saliva, Evasin-3, a highly selective CXC chemokine
binding protein and Evasin-4, a CC chemokine binding protein,
cloned by cross-linking to CCL5 and CCL11/Eotaxin[30].
Similarly, these proteins have unique sequences, but Evasin-4
has the same pattern of cysteine residues as Evasin-1, suggesting
that these two proteins will share a common fold. The resolution of
the structures of Evasin-1 and Evasin-3[30] has confirmed the
novelty of the structure of these proteins. An analysis of the
secondary structure pattern of Evasin-1 depicted in Figure 2 has
revealed no significant similarities with other known proteins.
Comparison of the Mode of Binding of Evasin-1
Compared to That of Other Chemokine Binding Proteins
Herpes or poxviruses express most soluble chemokine-binding
proteins identified or characterized to date. These proteins are
believed to disrupt chemokine interactions with host cell receptors or
glycosaminoglycans, the latter interaction being required for their
immobilization in the circulation. Among the best characterized of
these viral chemokine-binding proteins are the leporipoxvirus and
orthopoxvirus encoded viral CC chemokine inhibitor (vCCI) family,
which display selectivity towards CC chemokines[31]. These proteins
have been shown to not only have potent anti-chemokine activity in
vitro, but also to display anti-inflammatory activity in vivo [32]. The
binding mode of the small tick-derived Evasin-1 to CCL3 can be
compared to that of a much larger poxvirus-encoded CC chemokine-
binding protein to CCL4, a very close homologue of CCL3, since the
NMR solution structure of the complex has been determined (pdb
entry 2 ffk and 2 fin)[33,34]. The CCL3 and CCL4 sequences in the
complex structures are very similar, with over 60% identity and 70%
similarity, and the structures are verysimilar, as can be expected, with
the exception of the extreme N-termini of CCL3 and CCL4, with the
main chains displaying an important difference in position between
residues 1 and 10. The N-terminus of CCL4 in the vCCI:CCL4
complex closely resembles that of the uncomplexed crystal structure
of CCL3 (J. Dias, unpublished results), and the important movement
observed around the peptide bond between Pro8-Thr9 and Thr9-
Thr10 of CCL3 in the Evasin-1:CCL3 complex remains unique. The
chemokine-binding proteins are very different, however, in structure
(see Figure 7 ab), size (vCCI is 26 kDa compared to 10.4 kDa for
Evasin-1), and selectivity[31], but they both interact with a similar
region of the chemokine ligand (see Figure 7c). The complexes are
thus also very different in size, shape, and also in buried surface area
(2650 A ˚ 2 for the Evasin-1:CCL3 and only 1980 A ˚ 2 for the much
largervCCI:CCL4complex).Whilsttheregionofthechemokinethat
interactswiththechemokine-bindingproteinisthesame,manyofthe
specific amino acids involved in the interactions are not. The 6
important hydrogen bonding interactions between CCL3 Thr16-
Ser17-Arg18 and Evasin-1 are not reproduced in the vCCI:CCL4
complex, despite the close sequence similarity of CCL4 with CCL3
(identical except for residue 17, which is an Ala instead of a Ser).
Surprisingly, vCCI does have complementary residues in the vicinity
of CCL4, but the hydrogen bonds would appear to be rather weak
Figure 6. Electrostatic surface complementarity between Evasin-1 and CCL3. (A) The CCL3 molecule is displayed as a cyan-colored ribbon,
while the Evasin-1 is displayed as a molecular surface colored by surface electrostatic potential. (B) The complex in (A) is rotated 180u along a central
vertical axis and the Evasin-1 is displayed as a green ribbon and the CCL3 molecule as a molecular surface colored by surface electrostatic potential.
doi:10.1371/journal.pone.0008514.g006
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and between the Oe1o fG lu 1 4 3a n dt h eO c of Thr16 ofCCL4).The
b-strand at residues 10-11 of CCL3 induced by binding of Evasin-1 is
not present in the vCCI:CCL4 complex, due to the important
differences in the structure of the N-terminal regions of the two
chemokines. The interesting edge-to-face p-p interaction observed
between Phe13 of CCL3 and Phe14 of Evasin-1 is not present in the
vCCI:CCL4 complex, where the corresponding hydrophobic pocket
is composed, for the most part, of aliphatic hydrophobic side chains.
This is interesting because of the role attributed to the side chain of
Phe13 of CCL4 in receptor binding[35]. The important stacking
interaction between Phe29 of CCL3 and Trp89 of Evasin-1 is not
present in the vCCI:CCL4 complex, where the Tyr14 side chain of
CCL4 is found pointing into solution, and making no contact with
vCCI. It would thus appear that the interactions between the
chemokines with Evasin-1 or vCCI are not conserved.
The other class of virally-encoded chemokine binding proteins
for which a complex structure has been determined is the M3
decoy receptor from murine herpesvirus-68, whose structure with,
and without CCL2, a member of the CC chemokine family has
been determined[36]. The structure of this chemokine-binding
protein is quite different from that of either Evasin-1 or vCCI, as
shown in Figure 7c. The M3 protein is even larger than vCCI
(42 kDa), and appears to be a dimer in solution, the dimer binding
two molecules of chemokine to form a complex with a
stoichiometry of 2:2. The buried solvent accessible surface area
of the complex of approximately 2600 A ˚ 2 is similar to that
observed for the Evasin-1:CCL3 complex.
The chemokine that was initially used to determine the structure of
this complex was an obligate monomer version of CCL2, with the
Pro8 mutated to Ala; but the solution of the structure of the complex
containing the wild type CCL2 showed no differences [37]. In both
Figure 7. Stereo diagram comparing the structure of the complexes of CC chemokines with different CC chemokine binding
proteins. (A) Ribbon diagram of the complex of CCL3 with Evasin-1. CCL3 is displayed in cyan and Evasin-1 in green. (B) Ribbon diagram of the
complex of CCL4 with vCCI. CCL4 is displayed in cyan and vCCI in violet, (C) Ribbon diagram of the complex of CCL2 with M3 decoy receptor. CCL4 in
cyan and the M3 decoy receptor in mauve.
doi:10.1371/journal.pone.0008514.g007
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XCL1, the N-terminal areas of the chemokines were not observed in
the crystal structure. The M3 proteins make no interaction with the
Thr16-Ser17-Arg18 region that is so important in the case of the
CCL3-Evasin-1 complex, and a tyrosine residue in CCL2 replaces
the Phe13 residue in CCL3. It is interesting to note that an edge-to-
face p-p interaction would appear to take place between this Tyr13
and Tyr266 of M3, reinforcing the possibility that this residue plays
an important role in chemokine-receptor interaction. The important
stacking interaction observed between CCL3 Phe29 and Evasin-1
T r p 8 9i sa l s on o to b s e r v e di nt h eM 3 : C C L 2c o m p l e x ,s i n c et h i sp a r t
of the chemokine is not in close proximity to the M3 protein.
The examination of these three complexes, all of which contain
similar chemokines of the CC sub-class, highlights the amazingly
different ways in which nature has evolved binding modes to
neutralize chemokines. The most striking difference amongst the
chemokine binding proteins is, of course, their different sizes, and
binding modes. It is interesting to note that they all contain folds that
are unrelated to known protein folds. It would appear that the binding
to chemokine molecules has requirements that cannot be met by the
known classical protein folds commonly found in higher species.
Structural Basis for the Selectivity of Evasin-1
The tick Rhipicephalus sanguineus, also known as the common
brown dog tick, is usually found feeding on dogs but is known to
infest other mammalian species. In view of this broad host range of
it is likely that Evasin-1 is also able to inhibit CCL3 from other
species. We have shown that Evasin-1 is indeed able to bind to
mouse CCL3 with a comparable affinity to that measured for
human CCL3, but binding to CCL3 from other species has not
been tested. It was therefore interesting to determine how similar
the sequence of CCL3 is between species. The amino acid
sequence of CCL3 is remarkably conserved in mammals
(Figure 8a). For example, the Phe29 residue, which makes the
stacking interaction with Trp89 of Evasin-1, is conserved in all
mammalian species. The Thr16-Ser17-Arg18 region of CCL3 is
less well conserved between species. The Arg18 residue is replaced
by lysine in several mammalian species (notably dog), but this is a
conservative substitution that should not affect the selectivity of
Evasin-1, though it may affect the binding affinity. The Thr16
residue is far less well conserved in mammals, being replaced by
substantially different amino acids (Ile, Val, Ala and Tyr). In fact,
this is one of the least well-conserved residues in the mammalian
CCL3 family, and yet would appear to play an important in the
interaction between the two proteins, notably forming a hydrogen
bond with the peptide oxygen of Leu9 of Evasin-1. Ser17 is also
not particularly well conserved throughout the CCL3 family
either, despite its side chain forming several interactions with
Evasin-1. This loop cannot be responsible for the high selectivity
displayed by Evasin-1.
We believed that the solution of the structure of the complex of
Evasin-1 with CCL3 would reveal the reason for the surprising
Figure 8. Amino acid sequence alignments. (A) Alignment of mammalian CCL3 sequences. Fully conserved residues are background colored in
blue, highly conserved (.80% identity amongst the species shown) in dark grey, and poorly conserved (.60% identity) in light grey. (B) Alignment of
chemokines towards CCL3. The blue background identifies amino acids that are identical to CCL3. (C) Amino acid sequences of the chemokine chimera.
doi:10.1371/journal.pone.0008514.g008
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by the fact that modelling the sequence of CCL5 into the structure
of the complexed CCL3 suggested that Evasin-1 should bind this
chemokine, contrary to the experimental results, in which we were
never able to demonstrate CCL5 binding by cross-linking or by
surface plasmon resonance (Fig. 9a). CCL5 has the two
hydrophobic residues in the correct position that could bind to
F14 and W89 of Evasin-1, but no binding to CCL5 was observed
by the different assays we used. However our initial conclusion
that the two ‘‘p-p’’ interactions were the major binding forces
appeared to be incorrect, since the mutation of these hydrophobic
residues to Ala had only a small impact on the affinity for CCL3
(Fig. 9b). It should be noted that the affinity of the WT and the
F14AW89A Evasin-1 proteins was measured on immobilized
chemokine for a direct comparison, which consistently results in
significantly lower affinities (results not shown). Mutation of these
two residues had no impact on kon, but did affect koff, suggesting
that they play a role in the stability of the complex, rather than in
the selectivity of the binding protein for CCL3.
The next surprising finding was that Evasin-1 was capable of
binding a CCL3/CCL5 chimera (see Figure 9), in which the first
10 amino acids at the N- terminus were from CCL3, and the
subsequent 59 are from CCL5, with an affinity similar to the wild-
type CCL3. This was unexpected since the full-length CCL5 did
not show any affinity towards Evasin-1. Furthermore, the opposite
chimera, CCL5/CCL3, did not bind at all, thus illustrating the
importance of the amino terminal region. Moreover, the fact that
the affinity is unchanged for the D4 form of CCL3, the truncated
form found in biological fluids[38] indicates that the selectivity
resides in the 6 residues immediately preceding the CC motif.
These 6 amino acids are, not surprisingly, highly conserved
amongst the CCL3 of different species (Figure 8a). Of the six
amino acids immediately upstream of the CC motif,
4ADTPTA
10,
Asp6, Thr7 and Pro8 are extremely highly conserved in all
mammalian species and play an immediately identifiable role in
the structure of the complex; the side chain of Asp6 forming
important hydrogen bond interactions with the side chain of
Arg90 from Evasin-1, the main chain carbonyl of Thr7 by
interacting with the main chain nitrogen of Trp90 of Evasin-1, and
it would thus appear that Evasin-1 recognizes its target chemokine
through this sequence, and subsequently binds the rest of the
protein.
The major difference in the N-terminal amino acid sequence of
CCL5 when compared to CCL3 is the lack of a residue equivalent
to the Pro8 in CCL3. An insertion has to be made in the
alignment of the two sequences, since the residues Asp6 and Thr7
are conserved, and both make important contributions to the
complex interface. The lack of this residue could therefore be
responsible for the lack of affinity of Evasin-1 for CCL5. The Ka
for the CCL3/CCl5 chimera is reduced 3-fold compared to
CCL3, while the Kd is not particularly affected, suggesting that
CCL5 may play a negative role in the binding event, whilst not
unduly influencing the stability of the complex. It is thus probable
that the preferred ligand for Evasin-1 is actually CCL3 in which
the amino terminus serves as the ‘‘address’’ but that Evasin-1 is
capable of binding closely related family members albeit with a
slower on-rate, since the body of the chemokine will compensate
for the remainder of the binding interactions. It should be noted
that these hypotheses are drawn in an attempt to explain the
exquisite and perplexing selectivity of this binding protein and
remain to be substantiated with experimental evidence. However,
this current hypothesis is not supported by the affinity of Evasin-1
towards CCL18, since the sequence of the N-terminus of this
chemokine bears no resemblance to that of CCL3. However,
CCL18 was apparently derived through gene duplication of the
CCL3 gene[39], and whilst the structure of this protein is
unknown, there may be other structural features in CCL18 that
explain its affinity for Evasin-1.
There is evidence that ticks produce different chemokine
binding proteins at different times during the feeding cycle, in
contrast to the more non-selective strategy employed by viruses.
The reason for this is open to speculation, but may be associated
with the fact that ticks harbour a large genome (.1610
9 bases)
with the potential of encoding multiple CK binding proteins,
unlike viruses, which are limited by much smaller genomes.
Nevertheless it is of interest that although both Evasin-1 and
Evasin-3, which are distinct in terms of structure and sequence, are
both small proteins (,10 kDa) similar in size to protein binding
scaffolds such as single chain camelid antibodies, named
nanobodies[40] or scaffolds such as ankyrins[41,42] etc, that are
increasingly being developed as protein therapeutics. Parasites
such as ticks have apparently developed this strategy before
mankind, and the novelty of this chemokine-binding fold may
reveal features for neutralization of important immunomodulatory
proteins such as chemokines that could help us design improved
biological therapeutics. We are currently investigating the
importance of the different residues in the interaction between
Evasin-1 and CCL3, and the role this plays in the selectivity of
Evasin-1, by site-directed mutagenesis of both partners. Informa-
tion gained from such studies may enable the design of Evasins
with defined chemokine binding specificity that could be
therapeutically useful in inflammatory and infectious diseases,
and cancer.
Material and Methods
Baculovirus Production of Evasin-1
Evasin-1 was expressed in insect cells and purified by
chromatography as described elsewhere[43]. We amplified and
subcloned the full-length Evasin-1 cDNA, including its signal
peptide for secretion, into a pDEST8 expression vector (Invitro-
gen) with a 6-histidine tag sequence at the COOH-terminus.
Spodoptera frugiperda (Sf9) cells were transfected and the recombinant
virus was amplified using standard methods. Evasin-1 was
expressed using the baculovirus system in insect cells (Bac-to-
Bac, Life technologies/Invitrogen). Baculovirus harbouring full
length C-terminal His-tagged Evasin-1 ORF were then used to
infect either Sf9 insect cells in SF900 II medium (Invitrogen), or
Trichoplusia ni (High Five) (Tn5) insect cells in Ex-cell 405 medium
(JRH Biosciences), at 27uC (the yield obtained with Sf9 cells was
10 times lower, so Tn5 cell expression was used for scale-up). For
large-scale production, several 2-L flasks of Tn5 cells were grown
to a density of 2.0610
6 cells per mL, which were then infected
with recombinant virus at a multiplicity of infection (MOI) of 10.0.
Cultures were allowed to grow for 64 hours post-infection, before
the cells were harvested by centrifugation. The mature protein,
with its signal peptide cleaved, is secreted into the supernatant.
The supernatant was filtered and the volume of the supernatant
was reduced to 500 ml by tangential flow concentration and
dialyzed against 50 mM phosphate buffer pH 7.5, 0.3 M NaCl,
and 5 mM imidazole, and was immediately purified.
In order to obtain non-glycosylated protein, Evasin-1 was
expressed in the presence of tunicamycin, a known inhibitor of N-
linked glycosylation[44]. Tunicamycin (0.2 mg/ml) was added to
the culture media immediately before infection, and the expression
of the protein was followed by Western-blot. The non-glycosylated
protein was purified by methods identical to those used for the
glycosylated form.
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PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8514Figure 9. The N terminus of CCL3 is involved in the selectivity of Evasin-1 binding. Upper panels: sensograms obtained for binding
experiments, lower panels: kinetic parameters relative to binding experiments. A) Chemokine binding to immobilized Evasin-1. Sensogram
corresponding to CCL3/CCL5 (green) shows similar binding properties to CCL3 (red) and D4CCL3 (cyan); CCL5/CCL3 (light green), and CCL5 (blue) are
unable to bind, as is CXCL8. nd = not determined; the affinity of the chemokine was too low for accurate measurement. B) Evasin-1 WT (Black) or
F14A W89A (brown) to immobilized CCL3.
doi:10.1371/journal.pone.0008514.g009
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Both the glycosylated and non-glycosylated proteins were
soluble and were purified to homogeneity in three steps, using a
similar protocol. The his-tagged protein was captured initially
using an affinity column (Ni-NTA), which was followed by anionic
exchange (Q resource) and finally gel filtration (Superdex 100) on
a Pharmacia FPLC system. The final sample was concentrated up
to 10 mg/ml, in the final buffer (100 mM Tris-HCl, 100 mM
NaCl, pH 7.5) ready for crystallization purposes. The homogene-
ity of the sample was followed through all steps of the purification
by SDS-PAGE.
The glycosylated protein was heterogeneous; presenting a
smeared band in SDS-PAGE, corresponding to different species
of glycosylated protein, which was confirmed by isoelectric
focusing.
The non-glycosylated protein showed a single band on SDS-
PAGE, but the isoelectric focusing revealed two major bands,
which were separated in the anionic exchange (Q-Resource) step.
The two fractions were analysed by N-terminal sequencing and
mass spectrometry, which revealed that they had molecular masses
of 11286 Da and 11362 Da, respectively. The first fraction
(pI=6.0), which corresponded to the mass of the non-glycosylated
protein, yielded crystals, while the second fraction (pI=5.8) with
an extra 76 Da did not crystallize.
Crystallization and Structure Determination of the
Non-Glycosylated Evasin-1
Glycosylated Evasin-1 was submitted to deglycosylation studies
using different endoglycosidases (Endoglycosydase Hf, PNGaseF –
Peptide-N-Glycosydase F from New England Biolabs), and the
extent of digestion was followed through SDS-PAGE. After
deglycosylation the protein was re-purified and crystallization
was attempted. All the crystallization attempts using the
enzymatically de-glycosylated Evasin-1 produced only microcrys-
tals. We therefore decided to express the Evasin-1 in Tn5 cells in
the presence of tunicamycin, a N-glycosylation inhibitor [44].
Crystals of non-glycosylated Evasin-1 were obtained by vapour
diffusion, using hanging drops, in the presence of 3% PEG 4K,
0.2 M (NH4)2SO4 and 10% methylpentanodiol (MPD). These
crystals grow in one week at room temperature up to a maximum
size of 0.360.360.3 mm
3. The crystals belong to the space group
P212121 with unit-cell dimensions of a=39.60 A ˚, b=46.16 A ˚ and
c=99.59 A ˚. The solvent content is approximately 39%, with two
molecules of Evasin-1 per asymmetric unit (Mathews, 1968).
Heavy atom derivatives were screened at different concentrations
and with different soaking times, and the most successful
derivatives were prepared using 5 mM K2PtCl4 (24 hours) and
5 mM AuKCl4 (24 hours). Upon reaction with the heavy atoms,
the crystal diffraction quality decreased significantly presenting
severe anisomorphism and anisotropy. All datasets were collected
at the X06SA-PXI beamline of the Swiss Light Source (SLS) at the
Paul Scherrer Institute (PSI) in Villigen (Switzerland).
Data were indexed and processed using DENZO and
SCALEPACK from the HKL package[45]. Initial heavy atom
positions were determined by Patterson methods using
SHELX[46] and further refined with SHARP[47]. The quality
of the initial electron density map was significantly improved by
solvent flattening using SOLOMON[48] through the interface in
autoSHARP [49]. The results of the phasing calculations are
summarized in Table S2.
The initial model was traced with ARP-WARP[50], with 77 out
of 200 residues being assigned to the electron density. For
graphical interpretation of electron density, we used the software
packages O[51], COOT[52] and MAPMAN BONES[53] for the
initial electron-density skeletonisation. The initial model was
improved by visual inspection and model building with COOT
[52]. The model was refined to 1.70 A ˚ resolution using CNX[26],
with a final R-value of 22.6% and free-Rvalue of 26.9 (5% test set)
using the parameter set of Engh and Huber [54]. The data
processing of the high resolution data set and refinement statistics
are summarised in Table S3. We have found two monomers (A/B)
in the asymmetric unit corresponding to a solvent content of
39.0% (VM =2.02 A ˚ 3 Da
21) [25]. The final refined atomic model
comprises residues 5–91 of monomer A and residues 10–89 for
monomer B, with the missing residues not observed in the electron
density (comprising the N-terminal and the C-terminal 6-his tag).
Crystallization and Structure Determination of the
Glycosylated Evasin-1
The first crystals of glycosylated Evasin-1 produced in Tn5 cells
were obtained in sitting drops vapour diffusion screenings using
the 96 well Crystal Screen HT from Hampton Research.
Conditions containing 30% polyethylene glycol (PEG) 4K or
PEG 8K and 0.2 M (NH4)2SO4 produced microcrystals. After
optimisation hexagonal rod shaped crystals grow up to maximum
dimensions of 0.3–0.8 mm in 20 days in 18% PEG 4K and 0.4 M
AS, or 10 days in 17% PEG 4K, 0.3 M (NH4)2SO4 and 3%
dioxane. These crystals belong to the space group P31,221 with
unit cell a=b=116.69 A ˚, c=58.82 A ˚, and diffracted up to
3.75 A ˚ using synchrotron radiation. Using a different protein
preparation expressed in Sf9 cells, it was possible to obtain cubic
pyramid shaped crystals in 23% PEG 4K and 0.3 M (NH4)2SO4.
These crystals grow up to 0.260.260.2 mm
3 and a complete data
set was obtained up to 2.70 A ˚ using synchrotron radiation. These
crystals belong to the space group P212121, with unit cell
a=68.70 A ˚, b=70.49 A ˚, c=103.82 A ˚. The crystal structure of
the glycosylated version of Evasin-1 was solved later by molecular
replacement in AMORE[55] using the non-glycosylated Evasin-1
as a search model. We have found three monomers in the
asymmetric unit corresponding to a solvent content of 67%
(Mathews, 1968). The model was built using COOT[52] and
refined against the 2.70 A ˚ resolution data with CNX[26], with a
final R-value of 28.5% and with free-R value of 33.9 (5% test set).
The data processing and refinement statistics are summarised in
Table S4.
Crystallization and Structure Determination of the
Complex between Evasin-1 and CCL3
The human chemokine CCL3 variant DAla
1-CCL3 (A10T)
lacking the first alanine residue and presenting the mutation
A10T[56] was produced in E. coli BL21 (DE3), and it was
expressed and purified as described[57].
The complex between the non-glycosylated Evasin-1 and CCL3
was prepared by incubating Evasin-1 overnight at 4uC with an
excess of CCL3, in a molar ratio of 1:2.5, which was then captured
on an (Ni-NTA) affinity column. Complex formation was followed
by gel filtration analysis (Superose 12) of the peak fractions and
SDS-PAGE, and pooled according to homogeneity of the sample.
The fraction containing the complex was then concentrated to
10 mg/ml in 25 mM Tris-HCl pH 8.0, 100 mM NaCl. Crystals
of the complex were obtained at room temperature by vapour
diffusion, using sitting drops, in the presence of 24% PEG 3350,
0.2 M ammonium sulphate and 0.1 M HEPES pH 8.1. The
crystals appear in one month and continue to grow for another
month up to a maximum size of 0.260.260.2 mm
3. The crystals
belong to the space group P4332 with unit-cell dimensions of
a=b=c=104.384 A ˚. The solvent content is approximately
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per asymmetric unit[25].
The Evasin-1 position was located by molecular replacement
with AMORE[55], using the previously determined Evasin-1 as a
search model. The initial molecular replacement phases produced
electron density maps of very good quality where the missing
CCL3 monomer could be identified by visual inspection,
confirming that the correct molecular replacement solution was
found. The complex Evasin-1 and CCL3 model was traced using
ARP-WARP[50], with 149 out of 169 residues being docked
initially to the electron density. After visual inspection with
COOT[52] and refinement with CNX[26], the final model has an
R-value of 24.2 and a free R-value of 29.9 (5% test set) for all 30–
1.90 A ˚ data. The data processing and refinement statistics are
summarised in the Table 1. The refined atomic model of the
Evasin-1 and CCL3 complex comprises the residues 1–100 of
Evasin-1 and 2–67 of CCL3 with the last 2 residues from the C-
terminal of CCL3 not being observed.
Cloning, Expression and Purification of Chemokine the
Chimera CCL3/CXCL8 and CCL5/CCL3
The chemokine chimeras were produced essentially as described
elsewhere[58], subcloned into a pET30a expression vector, the
protein expressed in E. coli BL21(DE3) and the protein purified
following standard chemokine techniques[59].
In the first PCR step, the core of CXCL8 for CCL3/CXCL8 or
CCL3 for CCL5/CCL3 were amplified to obtain the sequence of
the chemokine lacking its N terminus sequence up to the CXC or
CC motif, replaced by the five last N terminal amino acids CCL3
or CCL5. The second PCR step generated the full sequence of the
N terminus of CCL3 or CCL5. After solubilisation of the inclusion
bodies in 6 M guanidine, both CCL3/CXCL8 or CCL5/CCL3
protein solutions were directly renatured by dropwise dilution at
4uC into 0.1 M Tris-HCl pH 8.0 containing 0.1 mM reduced
glutathione and 0.01 mM oxidized glutathione, to obtain a final
protein concentration of 50 mg/ml. In the case of the CCL5/
CCL3, the initiating methionine was retained when the protein is
expressed in E.coli and was subsequently removed by methionine
aminopetidase (MAP) (PeproTech) digestion. CCL5/CCL3 was
suspended at 1 mg/ml in 35 mM Tris/HCl pH 8, the MAP was
then added at a ratio enzyme: substrate of 1:19250 (w:w) and the
digestion carried out for 24 h at 37uC. The digested protein was
then purified on an analytic RP-HPLC as described previously,
quantified by UV at 280 nM, aliquoted and lyophilised.
Surface Plasmon Resonance Analyses
Real-time biomolecular interaction analyses were performed
using a BIAcore 3000 surface plasmon resonance (SPR) system.
Chemokine binding analyses were performed on immobilized
Evasin-1. Evasin-1 was suspended at 50 mg/ml in 10 mM sodium
acetate buffer pH 4.5 and directly immobilized on a CM4 chip
(Biacore) by a standard amine coupling chemistry with the Biacore
Amine coupling kit (Biacore) according to manufacturer’s
instructions, to reach a level of 300–400 response units (RU)
using the Biacore3000 Wizard software. A blank cell was prepared
as a control with the chemical coupling without any added protein.
Experiments were performed at 25uC and 30 ml/min using HBS-P
running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl and
0.005% surfactant P20) (Biacore). Chemokines were suspended
at 0.1 mg/ml in running buffer and for binding experiments and
all protein solutions were filtered through a 0.22 mm filter. The
injection time was 3 min followed by a dissociation time of
2.5 min after injection. The chip was regenerated using 50 mM
Glycine buffer, pH 2 for 30 s. For each experiment, chemokines
were injected in triplicate in random order.
For Evasin-1 WT and F14A W89A binding on immobilized
CCL3, the same procedures were applied with the following
changes: CCL3 was suspended at 25 mg/ml in 10 mM sodium
acetate buffer pH 4 and immobilized on the chip and Evasin-1
WT and F14A W89A were suspended at 1 mg/ml in running
buffer for binding experiments.
For the kinetic experiments, 6 dilutions of chemokines or
Evasin-1 WT and F14A W89A were prepared in running buffer,
filtered through a 0.22 mm filter, and injected over the
experimental and blank flow cells. The injection time was 3 min
followed by a dissociation time of 15 min and the chip was
regenerated using 50 mM Glycine pH 2 buffer for 30 s. Again,
each chemokine or Evasin-1 WT and F14A W89A dilution was
injected in triplicate in a random order.
For the analysis, the sensograms from the blank cell, in addition
to the sensograms obtained with the running buffer alone were
subtracted from the binding to remove the system noise. For the
kinetics, the association (ka) and the dissociation (kd) values were
determined simultaneously by globally fitting sensograms for an
entire range of chemokine concentrations according to the
langmuı ¨r-fitting model. The apparent equilibrium dissociation
constants (Kd) were determined from the mean kinetics values with
the equation: Kd=k d/ka.
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Table S1 List of the residues at the interface of the complex and
their main interactions. (A) residues from Evasin-1, and (B)
residues from CCL3.
Found at: doi:10.1371/journal.pone.0008514.s001 (0.01 MB
DOC)
Table S2 Data collection and MIRAS Phasing statistics
(SHARP)
Found at: doi:10.1371/journal.pone.0008514.s002 (0.01 MB
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Table S3 Summary of data collection and refinement statistics
for the native dataset 2 of Evasin-1
Found at: doi:10.1371/journal.pone.0008514.s003 (0.01 MB
DOC)
Table S4 Summary of data collection and refinement statistics
for the glycosylated Evasin-1
Found at: doi:10.1371/journal.pone.0008514.s004 (0.01 MB
DOC)
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